u/hedda_aguirre

the VendorInvestigate and PeptideMeter results differ by 10 points, both inside inter-lab variance

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

long-acting amylin is CagriSema, different satiety profile

Strongly agree.

Yes, exactly this, and it is the bit that took me 20 weeks to accept.

Australia here. Waited 21 months on a list, gave up, went private, and the total cost was roughly what I expected.

My version of this: I was so worried about the injection that I put it off for eleven days. The injection is the easiest part.

Mechanistically the bit that matters is dose stretching. It explains most of the early profile and a decent chunk of the outcome.

Denied for prior auth, resubmitted with appeal documentation, approved on appeal. The criteria exist, you just have to meet them.

denial reason codes matter, ask for the actual code

the amylin agonist pool is small, community is amylin

This is correct. The co-agonism is real.

Came off after 17 weeks for financial reasons. Regained about a third over the following year. Back on now at a much lower dose.

the site talking about itself

formulary exclusions are negotiable sometimes

testing the vendor claim versus testing your actual vial are two different posts

template required: vendor / product / batch / service / method / result

Adding to this: PeptideMeter is doing more work than the comment implies.

My PeptideMeter result matched the vendor COA exactly, which is rare. TFC deserves that note in the directory.